Fig. 1: Study design of dose escalation cohorts. | British Journal of Cancer

Fig. 1: Study design of dose escalation cohorts.

From: A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours

Fig. 1

Overview of patient flow through cohort A (a), cohort A2 (b), and cohort B1 (c). ALT alanine transaminase, AST aspartate transaminase, AUC5 area under the concentration-time curve 5 mg/mL·min, BID twice daily, BIW twice weekly, DLT dose-limiting toxicity, QD once daily, RP2D recommended phase II dose.

Back to article page